232 related articles for article (PubMed ID: 28155335)
21. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections.
Sachs-Barrable K; Lee SD; Wasan EK; Thornton SJ; Wasan KM
Adv Drug Deliv Rev; 2008 Mar; 60(6):692-701. PubMed ID: 18053611
[TBL] [Abstract][Full Text] [Related]
22. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
23. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
[TBL] [Abstract][Full Text] [Related]
24. [Amphotericin B. Lipid complex versus liposomes. Which, why, when?].
Pahissa A
Enferm Infecc Microbiol Clin; 1997 Jan; 15(1):1-3. PubMed ID: 9147499
[No Abstract] [Full Text] [Related]
25. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
Mohamed HA; Radwan RR; Raafat AI; Ali AE
Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
[TBL] [Abstract][Full Text] [Related]
26. Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity.
Razzaque MS; Hossain MA; Ahsan N; Taguchi T
Nephron; 2001 Nov; 89(3):251-4. PubMed ID: 11598385
[TBL] [Abstract][Full Text] [Related]
27. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
28. Long chain fatty acid conjugation remarkably decreases the aggregation induced toxicity of Amphotericin B.
Thanki K; Prajapati R; Sangamwar AT; Jain S
Int J Pharm; 2018 Jun; 544(1):1-13. PubMed ID: 29635057
[TBL] [Abstract][Full Text] [Related]
29. Characterization of amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Drug Dev Ind Pharm; 2004 May; 30(5):535-43. PubMed ID: 15244089
[TBL] [Abstract][Full Text] [Related]
30. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
31. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
32. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
33. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment.
Nimtrakul P; Tiyaboonchai W; Lamlertthon S
Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675
[TBL] [Abstract][Full Text] [Related]
34. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
35. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations.
Jansook P; Pichayakorn W; Ritthidej GC
Drug Dev Ind Pharm; 2018 Oct; 44(10):1693-1700. PubMed ID: 29936874
[TBL] [Abstract][Full Text] [Related]
36. Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis.
Sosa L; Clares B; Alvarado HL; Bozal N; Domenech O; Calpena AC
Nanomedicine; 2017 Oct; 13(7):2303-2312. PubMed ID: 28712917
[TBL] [Abstract][Full Text] [Related]
37. Nanoethosomal formulation for skin targeting of amphotericin B: an in vitro and in vivo assessment.
Kaur L; Jain SK; Manhas RK; Sharma D
J Liposome Res; 2015; 25(4):294-307. PubMed ID: 25547800
[TBL] [Abstract][Full Text] [Related]
38. Optimizing efficacy of Amphotericin B through nanomodification.
Barratt G; Bretagne S
Int J Nanomedicine; 2007; 2(3):301-13. PubMed ID: 18019830
[TBL] [Abstract][Full Text] [Related]
39. Disposition of aerosolized liposomal amphotericin B.
Lambros MP; Bourne DW; Abbas SA; Johnson DL
J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
[TBL] [Abstract][Full Text] [Related]
40. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.
Risovic V; Boyd M; Choo E; Wasan KM
Antimicrob Agents Chemother; 2003 Oct; 47(10):3339-42. PubMed ID: 14506053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
